• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A leading pure play vaccine company.

ABR_Website_Image.jpg

— Mai 11, 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Read more

— Stock information

@valnevase




















-
— April 18, 2017
Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Read more
— Financial Calendar

June 29, 2017
Annual General Meeting 2017

August 31, 2017
HY 2017 Financial Statements

November 9, 2017
Q3 2017 Interim Results

See all dates


KOL event in N.Y. on Lyme disease (webcast)



JAPANESE
ENCEPHALITIS
AND
CHOLERA



learn more
play video Valneva's CEO Thomas Lingelbach
comments on Group Strategy

– Upcoming conferences and fairs



Gilbert Dupont Midcap Healthcare Forum
Paris, France
May 30, 2017

Jefferies 2017 Global Healthcare Conference
New York, US
June 6-9, 2017

Kepler Biotech Days
Paris, France
June 8-9, 2017


Please update your browser...